MaxCyte Inc (MXCT) Ord USD0.01 (DI)
- Add to watchlist
- Create an alert
- This stock can be held in a
374.00p
394.00p
415.00p
£410.33 million
368.00p
377.60p
256.00p
n/a
17.00p (4.84%) Previous:
17.00p
201,321
n/a
750
Performance
1 week 1W | 14.41% | 1 year 1Y | 7.38% |
---|---|---|---|
1 month 1M | 16.47% | 2 years 2Y | 12.58% |
3 months 3M | 31.86% | 3 years 3Y | 31.75% |
6 months 6M | 11.78% | 5 years 5Y | 208.73% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 41.29 | 44.26 |
Profit before tax ($m) | (37.92) | (23.57) |
Adjusted EPS (¢): | (37.00) | (54.87) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
MaxCyte flags full-year revenue at top end of expectations
13 January 2025 14:34
-
MaxCyte upgrades revenue guidance after operational review
9 December 2024 08:55
-
MaxCyte appoints new chief commercial officer
10 October 2024 13:23
-
Preliminary Fourth Quarter and Full Year Results
13 January 2025 08:05
-
Total Voting Rights
2 January 2025 17:53
-
Exercise of options and PDMR dealing
31 December 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.